U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C34H41N7O5
Molecular Weight 627.7332
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DABIGATRAN ETEXILATE

SMILES

CCCCCCOC(=O)NC(=N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=NC=CC=C4)N2C)C=C1

InChI

InChIKey=KSGXQBZTULBEEQ-UHFFFAOYSA-N
InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

HIDE SMILES / InChI

Molecular Formula C34H41N7O5
Molecular Weight 627.7332
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf https://www.pradaxa.com/

Dabigatran ethyl ester is a one of the intermediate, which is formed during metabolic reactions from dabigatran etexilate. Dabigatran ethyl ester forming under the action of intestinal carboxylesterase 2 (CES2) further is hydrolyzed by CES1 with formation of active drug, thrombin inhibitor, dabigatranand. Dabigatran ethyl ester is a much stronger inhibitor of ribosyldihydronicotinamide dehydrogenase, than dabigatran.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

1.28735995E12
Primary
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

1.28735995E12
Preventing
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

1.28735995E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
348 ng/mL
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2232 ng × h/mL
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day single, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: single
Dose: 400 mg, 3 times / day
Sources: Page: p.301
healthy, 18–45
n = 8
Health Status: healthy
Age Group: 18–45
Sex: M
Population Size: 8
Sources: Page: p.301
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.301
healthy, 18–45
n = 6
Health Status: healthy
Age Group: 18–45
Sex: M
Population Size: 6
Sources: Page: p.301
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Disc. AE: C-reactive protein increased, Alanine aminotransferase increase...
AEs leading to
discontinuation/dose reduction:
C-reactive protein increased (7.14%)
Alanine aminotransferase increase (7.14%)
Haematuria (7.14%)
Epistaxis (7.14%)
Haemorrhoidal haemorrhage (7.14%)
Sources: Page: p.605
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.5
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.5
Disc. AE: Bleeding, Gastrointestinal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Bleeding
Gastrointestinal disorder NOS
Sources: Page: p.5
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.6
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.6
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 5, 0.07%)
Sources: Page: p.6
150 mg 2 times / day multiple, oral (max)
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Sources: Page: p.1
Disc. AE: Spinal epidural hematoma, Bleeding...
AEs leading to
discontinuation/dose reduction:
Spinal epidural hematoma
Bleeding (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Alanine aminotransferase increase 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
C-reactive protein increased 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Epistaxis 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Haematuria 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Haemorrhoidal haemorrhage 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Bleeding Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.5
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.5
Gastrointestinal disorder NOS Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.5
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.5
Bleeding grade 5, 0.07%
Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.6
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.6
Spinal epidural hematoma Disc. AE
150 mg 2 times / day multiple, oral (max)
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Sources: Page: p.1
Bleeding grade 3-5
Disc. AE
150 mg 2 times / day multiple, oral (max)
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: Coadministration of Atorvastatin (CYP3A4 & P-gp inhibitor, 400 mg QD x 4 days) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) decreased total Dabigatran AUCtau,ss by 58% and Cmax,ss by 50%., Coadministration of Clarithromycin (CYP3A4 & P-gp inhibitor, 500 mg BID x 5 days & 500 mg QD on Day 6) with Dabigatran metexilate mesylate (150 mg QD on Day 6) increased total Dabigatran AUCinf by 19% and Cmax by 15%., Coadministration of Rifampicin (CYP3A4 & P-gp inducer, 600 mg QD x 7 days in the night) with Dabigatran metexilate mesylate (150 mg QD on Day 8 morning) decreased total Dabigatran AUCinf by 67% and Cmax by 66%., Coadministration of Ketoconazole (CYP3A4 & P-gp inhibitor, 400mg QD ) with Dabigatran metexilate mesylate (150 mg QD) increased total Dabigatran AUCinf by 138% and Cmax by 135%.
Page: (ClinPharm) 13, (PMDA_A100_1 Japanese) 32, 40-41, (PMDA_I100_1 Japanese) 33
no
no (co-administration study)
Comment: Caco-2 cells, Efflux ratio = 1.09 (3 mcM), 0.95 (300 mcM); MDR1-LLC-PK1 cells, Efflux ratio = 1.35 (10 mcM); Coadministration of Amiodarone (P-gp & CYP2C9 inhibitor, 600 mg QD on Day 4) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) increased total Dabigatran AUCtau,ss by 58% and Cmax by 50%., Coadministration of Verapamil (P-gp inhibitor, 120 mg single or multiple doses, or 240 mg single dose) with Dabigatran metexilate mesylate (150 mg single dose) increased total Dabigatran AUCinf by 39~143% and Cmax by 12~179%., Coadministration of Quinidine (200 mg every 2 hr x 5 on Day 3 (3 hr after the first Dabigatran dose), P-gp inhibitor) with Dabigatran metexilate mesylate (150 mg BID x 3 days (2nd dose on Day 3 was administrated 1 hr after the final Quinidine dose) increased total Dabigatran AUCtau,ss by 53% and Cmax,ss by 56%., Coadministration of Ketoconazole (CYP3A4 & P-gp inhibitor, 400mg QD ) with Dabigatran metexilate mesylate (150 mg QD) increased total Dabigatran AUCinf by 138% and Cmax by 135%., Coadministration of Atorvastatin (CYP3A4 & P-gp inhibitor, 400 mg QD x 4 days) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) decreased total Dabigatran AUCtau,ss by 58% and Cmax,ss by 50%., Coadministration of Clarithromycin (CYP3A4 & P-gp inhibitor, 500 mg BID x 5 days & 500 mg QD on Day 6) with Dabigatran metexilate mesylate (150 mg QD on Day 6) increased total Dabigatran AUCinf by 19% and Cmax by 15%., Coadministration of Rifampicin (CYP3A4 & P-gp inducer, 600 mg QD x 7 days in the night) with Dabigatran metexilate mesylate (150 mg QD on Day 8 morning) decreased total Dabigatran AUCinf by 67% and Cmax by 66%.
Page: 54-55, 56-57, (ClinPharm) 12, 13, 33-36, (PMDA_A100_1 Japanese) 33, 39, 40-41, (PMDA_I100_1 Japanese) 66, (PMDA_K103_1 Japanese) 152-156
yes [Km 371.4 uM]
yes [Km 511.7 uM]
yes [Km 987.3 uM]
Tox targets
PubMed

PubMed

TitleDatePubMed
[Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches].
2006 May
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
2006 Nov
Investigational treatments of venous thromboembolism.
2007 Apr
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
2007 Jun
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
2008
New issues in oral anticoagulants.
2008
Dabigatran etexilate.
2008
[New anticoagulants].
2008 Feb
Update on atrial fibrillation: part I.
2008 Feb
New oral anticoagulants in atrial fibrillation.
2008 Jan
New developments in anticoagulation for atrial fibrillation.
2008 Sep
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.
2009
Use of anticoagulants in elderly patients: practical recommendations.
2009
[New anticoagulants for secondary haemostasis--anti IIa inhibitors].
2009 Aug
Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
2009 Aug
Recent developments in the use of oral anticoagulants.
2009 Aug
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
2009 Aug
Enhancement of pig embryonic implants in factor VIII KO mice: a novel role for the coagulation cascade in organ size control.
2009 Dec 21
Dabigatran versus warfarin in patients with atrial fibrillation.
2009 Dec 31
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
2009 Jan
New anticoagulants: focus on venous thromboembolism.
2009 Jul
The prevention of hospital-acquired venous thromboembolism in the United Kingdom.
2009 Mar
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
2009 May
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
2009 Nov
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.
2009 Nov 3
Dabigatran etexilate in venous thromboembolism.
2009 Oct
[New developments in antithrombotic care].
2009 Sep
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
2010 Apr
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
2010 Feb
New oral anticoagulants: a practical guide for clinicians.
2010 Feb
The new oral anticoagulants.
2010 Jan 7
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
2010 Mar
Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
2010 Mar
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
2010 Sep
Patents

Sample Use Guides

Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis Recommended doses: 150 mg orally twice a day Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation Recommended doses: 150 mg orally twice a day Usual Adult Dose for Deep Vein Thrombosis/Pulmonary Embolism Prophylaxis Following Hip Replacement Surgery 110 mg orally 1 to 4 hours after surgery and after hemostasis has been achieved, then 220 mg orally once a day for 28 to 35 days
Route of Administration: Oral
Dabigatran at higher concentrations (500 and 1000 nM) potently inhibited thrombus formation. In platelet-poor plasma, dabigatran at 250 and 500 nM efficiently prolonged the lag time (LT) and moderately reduce peak height (PH) of TG.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:56:08 UTC 2023
Edited
by admin
on Wed Jul 05 23:56:08 UTC 2023
Record UNII
2E18WX195X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DABIGATRAN ETEXILATE
INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
DABIGATRAN ETEXILATE [MART.]
Common Name English
BIBR-1048
Code English
DABIGATRAN ETEXILATE [VANDF]
Common Name English
PRADAXA (DABIGATRAN ETEXILATE)
Common Name English
dabigatran etexilate [INN]
Common Name English
BIBR1048
Code English
ETHYL 3-(((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)(PYRIDIN-2-YL)AMINO)PROPANOATE
Systematic Name English
Dabigatran etexilate [WHO-DD]
Common Name English
.BETA.-ALANINE, N-((2-(((4-((((HEXYLOXY)CARBONYL)AMINO)IMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-, ETHYL ESTER
Common Name English
BIBR 1048 BS RS1
Code English
PRAZAXA
Brand Name English
PRADAXA
Brand Name English
DABIGATRAN ETEXILATE METHANESULFONATE [JAN]
Common Name English
DABIGATRAN ETEXILATE [MI]
Common Name English
DABIGATRAN ETEXILATE [USAN]
Common Name English
BIBR-1048-BS-RS1
Code English
Ethyl 3-{[(2-{[(4-{[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl](pyridin-2-yl)amino}propanoate
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
WHO-VATC QB01AE07
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
WHO-ATC B01AE07
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
Code System Code Type Description
CHEBI
70743
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
DAILYMED
2E18WX195X
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
DRUG BANK
DB06695
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
PUBCHEM
213023
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
EVMPD
SUB20521
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
CAS
211915-06-9
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
MERCK INDEX
M4064
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY Merck Index
SMS_ID
100000089553
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
RXCUI
1037042
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
776
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL539697
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
USAN
UU-126
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID4057681
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
INN
8028
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
NCI_THESAURUS
C87480
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
CHEBI
70746
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
IUPHAR
6379
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
FDA UNII
2E18WX195X
Created by admin on Wed Jul 05 23:56:08 UTC 2023 , Edited by admin on Wed Jul 05 23:56:08 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA; URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA
Related Record Type Details
ACTIVE MOIETY